Drug transport to brain with targeted nanoparticles

NeuroRx

Volumn 2, Issue 1, 2005, Pages 108-119

  Olivier, Jean Christophe ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

Blood brain barrier; Brain targeting; Immunonanoparticle; Nanoparticle; PEG; Transcytosis

Indexed keywords

ACRYLIC ACID DERIVATIVE; DRUG CARRIER; IMMUNOLIPOSOME; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; MACROGOL 2000; MACROGOL 3000; METHOXYPOLY(ETHYLENE GLYCOL)POLYLACTIDE; NANOPARTICLE; PEPTIDE; PLASMID DNA; POLOXAMER; POLY(BUTYL 2 CYANOACRYLATE); POLYGLACTIN; POLYLACTIDE; POLYPEPTIDE; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN; CHEMICAL STRUCTURE; DRUG COATING; DRUG CONJUGATION; DRUG SOLUBILITY; DRUG TRANSPORT; MOLECULAR WEIGHT; NONHUMAN; REVIEW;

EID: 12344307628     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.1.108     Document Type: Article

References (150)

1. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1-20, 2001.
2. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257-1272, 2004.
3. Gref R, Domb A, Quellec P, Blunk T, Müller RH, Verbavatz JM, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215-233, 1995.
4. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28:1-13, 2002.
5. Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge, UK: Cambridge University Press, Inc., 2001.
6. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 41:44-48, 1995.
7. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171-174, 1995.
8. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P. Nanocapsules: a new type of lysosomotropic carrier. FEBS Lett 84: 323-326, 1977.
9. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55:519-548, 2003.
10. Guise V, Drouin JY, Benoit J, Mahuteau J, Dumont P, Couvreur P. Vidarabine-loaded nanoparticles: a physicochemical study. Pharm Res 7:736-741, 1990.
11. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to oxicity. Pharm Res 16:1836-1842, 1999.
12. Olivier JC, Vauthier C, Taverna M, Puisieux F, Ferrier D Couvreur P. Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. J Control Release 40:157-168, 1996.
13. Muller RH, Lherm C, Herbort J, Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 11:590-595, 1990.
14. Müller R H, Lherm C, Herbort J, Blunk T, Couvreur P. Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length. Int J Pharm 84:1-11, 1992.
15. Lherm C, Müller RH, Puisieux F, Couvreur P. Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int J Pharm 84:13-22, 1992.
16. Kante B, Couvreur P, Dubois-Krack G, De Meester C, Guiot P, Roland M, et al. Toxicity of polyalkylcyanoaerylate nanoparticles I: free nanoparticles. J Pharm Sci 71:786-790, 1982.
17. Kattan J, Droz JP, Couvreur P, Marino JP, Boutan-Laroze A, Rougier P, et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs 10:191-199, 1992.
18. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 15:335-345, 1983.
19. Douglas S J, Davis SS, Illum L. Biodistribution of poly (butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm 34:145-152, 1986.
20. Waser PG, Müller U, Kreuter J, Berger S, Munz K, Kaiser E, et al. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int J Pharm 39:213-227, 1987.
21. Simeonova M, Ivanova T, Raikova E, Georgieva M, Raikov Z. Tissue distribution of polybutylcyanoacrylate nanoparticles carrying spin-labelled nitrosourea. Int J Pharm 43:267-271, 1988.
22. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol 26:13-18, 1990.
23. Lobenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 50:21-30, 1998.
24. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121-128, 1999.
25. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-1569, 1999.
26. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-767, 2004.
27. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325-328, 1997.
28. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate study. J Microencapsul 15:67-74, 1998.
29. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81, 2001.
30. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Control Release 49:81-87, 1997.
31. Allemann E, Gravel P, Leroux JC, Balant L, Gurny R. Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J Biomed Mater Res 37:229-234, 1997.
32. Gref R, Luck M, Quellec P, Marchand M, Dellaeherie E, Harnisch S. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surfaces B: Biointerfaces 18:301-313, 2000.
33. Lode J, Fichtner I, Kreuter J, Berndt A, Diederichs JE, Reszka R. Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models. Pharm Res 18:1613-1619, 2001.
34. Darius J, Meyer FP, Sabel BA, Schroeder U. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 52:1043-1047, 2000.
35. Schroeder U, Schroeder H, Sabel BA. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci 66:495-502, 2000.
36. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157-1166, 2001.
37. Azmin MN, Stuart JF, Florence AT. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 14:238-242, 1985.
38. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 9:209-221, 2001.
39. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49: 103-109, 2000.
40. Vert M, Schwach G, Engel R, Coudane J. Something new in the field of PLA/GA bioresorbable polymers? J Control Release 53: 85-92, 1998.
41. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-24, 1997.
42. Ueda H, Tabata Y. Polyhydroxyalkanonate derivatives in current clinical applications and trials. Adv Drug Deliv Rev 55:501-518, 2003.
43. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 48:342-353, 1999.
44. Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A, et al. Body distribution of fully biodegradable [14 C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 13:1093-1102, 1992.
45. von Burkersroda F, Gref R, Gopferich A. Erosion of biodegradable block copolymers made of poly(D,L-lactic acid) and poly(ethylene glycol). Biomaterials 18:1599-1607, 1997.
46. Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, Alonso MJ. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res 42:45-54, 1998.
47. Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, et al. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 17:1575-1581, 1996.
48. Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein encapsulation within polyethylene glycol-coated nanospheres. II. Controlled release properties. J Biomed Mater Res 47:388-395, 1999.
49. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. Int J Pharm 212:1-9, 2001.
50. Working PK, Newman MS, Johnson J, Cornacoff JB. Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives. In: Poly(ethylene glycol): chemistry and biological applications (Harris JM, Zalipsky S, eds.) ACS Symposium Series, No 680, pp 45-57. Washington, DC: American Chemical Society, 1997.
51. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials 17:2191-2197, 1996.
52. Emerich DF, Tracy MA, Ward KL, Figueiredo M, Qian R, Henschel C, et al. Biocompatibility of poly (DL-lactide-co-glycolide) microspheres implanted into the brain. Cell Transplant 8:47-58, 1999.
53. Menei P, Daniel V, Montero-Menei C, Brouillard M, Pouplard-Barthelaix A, Benoit JP. Biodegradation and brain tissue reaction to poly(D,L-lactide-co- glycolide) microspheres. Biomaterials 14: 470-478, 1993.
54. 50 nanoparticles after single dose intravenous administration to rat. Colloids Surfaces B: Biointerfaces 16:173-183, 1999.
55. Lee J, Cho EC, Cho K. Incorporation and release behavior of hydrophobic drug in functionalized poly(D,L-lactide)-block-poly(ethylene oxide) micelles. J Control Release 94:323-335, 2004.
56. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, Labrude P, Vigneron C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J Control Release 50:31-40, 1998.
57. Chognot D, Six JL, Leonard M, Bonneaux F, Vigneron C, Dellacherie E. Physicochemical evaluation of PLA nanoparticles stabilized by water-soluble MPEO-PLA block copolymers. J Colloid Interface Sci 268:441-447, 2003.
58. Riley T, Govender T, Stolnik S, Xiong CD, Garnett MC, Illum L, et al. Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles. Colloids Surfaces B: Biointerfaces 16:147-159, 1999.
59. Riley T, Stolnik S, Heald CR, Xiong CD, Garnett MC, Illum L, et al. Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. Langmuir 17:3168-3174, 2001.
60. Niwa T, Takeuchi H, Hino T, Nohara M, Kawashima Y. Biodegradable submicron carriers for peptide drugs: preparation of -lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate by a novel emulsion-phase separation method in an oil system. Int J Pharm 121:45-54, 1995.
61. Horisawa E, Hirota T, Kawazoe S, Yamada J, Yamamoto H, Takeuchi H, Kawashima Y. Prolonged anti-inflammatory action of DL-lactide/glycolide copolymer nanospheres containing beta-methasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm Res 19:403-410, 2002.
62. Konan YN, Gurny R, Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 233:239-252, 2002.
63. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker, E, et al. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res 16:859-866, 1999.
64. Scholz C, Iijima M, Nagasaki Y, Kataoka K. A novel reactive polymeric micelle with aldehyde groups on its surface. Macromolecules 28:7295-7297, 1995.
65. Hagan SA, Coombes AGA, Garnett MC, Dunn SE, Davies MC, Illum L, et al. Polylactide-poly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-forming systems. Langmuir 12:2153-2161, 1996.
66. Stolnik S, Heald CR, Neal J, Garnett MC, Davis SS, Illum L, et al. Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target 9:361-378, 2001.
67. Heald CR, Stolnik S, Kujawinski KS, De Matteis C, Garnett MC, Illum L. Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona. Langmuir 18:3669-3675, 2002.
68. Gref R, Babak B, Bouillot P, Lukina I, Bodorev M, Dellacherie E. Interfacial and emulsion stabilising properties of amphiphilic water-soluble poly(ethylene glycol)-poly(lactic acid) copolymers for the fabrication of biocompatible nanoparticles. Colloids Surfaces A 143:413-420, 1998.
69. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett 532:338-344, 2002.
70. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42:463-478, 2003.
71. Heald CR, Stolnik S, De Matteis C, Garnett MC, Illum L, Davis SS, et al. Characterisation of poly(lactic acid):poly(ethyleneoxide) (PLA:PEG) nanoparticles using the self-consistent theory modelling approach. Colloids Surfaces A 212:57-64, 2003.
72. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 11:1800-1808, 1994.
73. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J Control Release 36:49-61, 1995.
74. Le Ray AM, Vert M, Gautier JC, Benoît JP. Fate of [14C]poly(-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int J Pharm 106:201-211, 1994.
75. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 71:203-211, 2001.
76. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53: 283-318, 2001.
77. Sahli H, Tapon-Bretaudiere J, Fischer AM, Sternberg C, Spenlehauer G, Verrecchia T, et al. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomaterials 18:281-288, 1997.
78. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 84:493-498, 1995.
79. Zambaux MF, Faivre-Fiorina B, Bonneau F, Marchal S, Merlin JL, Dellacherie E, et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials 21:975-980, 2000.
80. Mosqueira VC, Legrand P, Gulik A, Bourdon O, Gref R, Labarre D, et al. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967-2979, 2001.
81. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603, 1994.
82. 125I-PLA-b-PEO block copolymers in rats. Pharm Dev Technol 8:153-161, 2003.
83. Moghimi SM. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim Biophys Acta 1590:131-139, 2002.
84. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 10:1732-1737, 1993.
85. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 70:63-70, 2001.
86. Onishi H, Machida Y, Machida Y. Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol). Biol Pharm Bull 26:116-119, 2003.
87. Dong Y, Feng SS. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25:2843-2849, 2004.
88. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 11:413-424, 2004.
89. Ameller T, Marsaud V, Legrand P, Gref R, Renoir JM. Pure antiestrogen RU 58668-loaded nanospheres: morphology, cell activity and toxicity studies. Eur J Pharm Sci 21:361-370, 2004.
90. Fishbein I, Chorny M, Rabinovich L, Banai S, Gati I, Golomb G. Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis. J Control Release 65:221-229, 2000.
91. Peracchia MT, Gref R, Minamitake Y, Domb A, Lotan N, Langer R. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: investigation of their drug encapsulation and release characteristics. J Control Release 46:223-231, 1997.
92. Ubrich N, Bouillot P, Pellerin P, Hoffman M, Maincent P. Preparation and characterization of propranolol hydrochloride nanoparticles: a comparative study. J Control Release 97:291-300, 2004.
93. Hoffart V, Ubrich N, Simonin C, Babak V, Vigneron C, Hoffman M, et al. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release charaeteristics. Drug Dev Ind Pharm 28:1091-1099, 2002.
94. Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 239:113-120, 2002.
95. Nicoli S, Santi P, Couvreur P, Couarraze G, Colombo P, Fattal E. Design of triptorelin loaded nanospheres for transdermal iontophoretic administration. Int J Pharm 214:31-35, 2001.
96. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57: 171-185, 1999.
97. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm 199:95-110, 2000
98. Panyam J, Williams D, Dash A, Leslie-Pelecky D, Labhasetwar V. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci 93:1804-1814, 2004.
99. Hiroaki O, Yamamoto M, Heya T, Inoue Y, Kamei S, Ogawa Y, et al. Drug delivery using biodegradable microspheres. J Control Release 28:121-129, 1994.
100. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J Pharm Sci 83:727-732, 1994.
101. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 82:17-27, 2002.
102. Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int J Pharm 278:133-141, 2004.
103. Matsumoto J, Nakada Y, Sakurai K, Nakamura T, Takahashi Y. Preparation of nanoparticles consisted of poly(L-lactide)-poly-(ethyleneglycol)-poly(L- lactide) and their evaluation in vitro. Int J Pharm 185:93-101, 1999.
104. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm 43:287-294, 1997.
105. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270-275, 1998.
106. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly(lactic acid)-poly(ethylene glycol)PEG micro- and nanoparticles. Comparison with conventional PLA particulate carriers. Eur J Pharm Biopharm 51:111-118, 2001.
107. Kawashima Y, Yamamoto H, Takeuchi H, Hino T, Niwa T. Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 45:41-48, 1998.
108. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(d,l-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22: 2406-2412, 2004.
109. Lucke A, Fustella E, Tessmar J, Gazzaniga A, Gopferich A. The effect of poly(ethylene glycol)-poly(D,L-lactic acid) diblock copolymers on peptide acylation. J Control Release 80:157-168, 2002.
110. van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17:1159-1167, 2000.
111. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98, 2002.
112. Cleland JL. Protein delivery from biodegradable microspheres. Pharm Biotechnol 10:1-43, 1997.
113. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J Control Release 60:179-188, 1999.
114. Gaspar MM, Blanco D, Cruz MEM, Alonso MJ. Formulation of -asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J Control Release 52:53-62, 1998.
115. Pean JM, Boury F, Venier-Julienne MC, Menei P, Proust JE, Benoit JP. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm Res 16:1294-1299, 1999.
116. Pean JM, Menei P, Morel O, Montero-Menei CN, Benoit JP. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials 21: 2097-2101, 2000.
117. Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-α. Eur J Pharm Sci 18:221-229, 2003.
118. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J Control Release 58:143-151, 1999.
119. Morlock M, Koll H, Winter G, Kissel T. Microencapsulation of rh-erythropoietin, using biodegradable poly(D,L-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. Eur J Pharm Biopharm 43:29-36, 1997.
120. Perez C, Sanchez A, Putnam D, Ting D, Langer R, Alonso MJ. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 75:211-224, 2001.
121. Prabha S, Zhou WZ, Panyam J, Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 244:105-115, 2002.
122. Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle-mediated gene expression. Pharm Res 21:354-364, 2004.
123. Labhasetwar V, Bonadio J, Goldstein SA, Levy RJ. Gene transfection using biodegradable nanospheres: results in tissue culture and a rat osteotomy model. Colloids Surfaces B: Biointerfaces 16:281-290, 1999.
124. Davda J, Labhasetwar V. Characterization of nanoparticle uptake by endothelial cells. Int J Pharm 233:51-59, 2002.
125. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347, 2003.
126. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16: 1217-1226, 2002.
127. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 82:105-114, 2004.
128. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 4:183-194, 2002.
129. Delie F, Berton M, Allemann E, Gurny R. Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles. Int J Pharm 214:25-30, 2001.
130. Berton M, Allemann E, Stein CA, Gurny R. Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex. Eur J Pharm Sci 9:163-170, 1999.
131. Berton M, Benimetskaya L, Allemann E, Stein CA, Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm 47:119-123, 1999.
132. 50 nanoparticles by complexation with structures oligopeptides. Drug Deliv 3:187-195, 1996.
133. Berton M, Benimetskaya L, Allemann E, Stein CA, Gurny R. Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization. Eur J Pharm Biopharm 47:119-123.
134. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169, 1996.
135. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11-18, 2003.
136. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 98:12754-12759, 2001.
137. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 97:7567-7572, 2000.
138. Zhang Y, Boado RJ, Pardridge WM. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 20:1779-1785, 2003.
139. Salem AK, Cannizzaro SM, Davies MC, Tendler SJ, Roberts CJ, Williams PM, et al. Synthesis and characterisation of a degradable poly(lactic acid)-poly(ethylene glycol) copolymer with biotinylated end groups. Biomacromolecules 2:575-580, 2001.
140. Tessmar J, Mikos A, Gopferich A. Amine-reactive biodegradable diblock copolymers. Biomacromolecules 3:194-200, 2002.
141. Tessmar J, Mikos A, Gopferich A. The use of poly(ethylene glycol)-block-poly(lactic acid) derived copolymers for the rapid creation of biomimetic surfaces. Biomaterials 24:4475-4486, 2003.
142. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137-1143, 2002.
143. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459-476, 2002.
144. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 96:273-283, 2004.
145. Gref R, Couvreur P, Barratt G, Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 24:4529-4537, 2003.
146. Kang YS, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J Drug Target 3:159-165, 1995.
147. Yamamoto Y, Nagasaki Y, Kato M, Kataoka K. Surface charge modulation of poly(ethylene glycol)poly(L-lactide) block copolymer micelles: conjugation of charged peptides. Colloids Surfaces B: Biointerfaces 16:135-146, 1999.
148. Emoto K, Nagasaki Y, lijima M, Kato M, Kataoka K. Preparation of non-fouling surface through the coating with core-polymerized block copolymer micelles having aldehyde-ended PEG shell. Colloids Surfaces B: Biointerfaces 18:337-346, 2000.
149. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(-lactide) block copolymer micelles with modulated surface charge. J Control Release 77:27-38, 2001.
150. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 92:5592-5596, 1995.